Abstract:Aims: Perfluorocarbons (PFCs) are inert, oxygen-rich fluids with applications in neonatal and adult liquid ventilation and potential for innovations related to hypoxic environments, such as under water and for space. Despite promising clinical applications, a laboratory model to comprehensively test PFC implications and predict human airway responses is lacking. We hypothesise that an organotypic airway epithelial cell (AEC) model is needed assess PFC impacts and provide predictive outcomes to inform the in vivo scenario that conventional submerged cultures cannot replicate. This study evaluated PFC exposure in two in vitro systems: a traditional submerged model using 16HBE14o- cells and an air-liquid interface (ALI) model using hSABCi and primary nasal AECs, cultured on transwells to mimic the human airway epithelium. Methods: PFC exposures were conducted at 2, 8, and 24 hours (submerged model) and extended to 72 hours (ALI model). We tracked gross morphological changes via microscopy, quantified apoptosis and autophagy markers through protein biochemistry, and assessed epithelial permeability using trans-epithelial electrical resistance (TEER) and tight junction protein abundance. Statistical analyses included at least three biological replicates per condition. Results: In the submerged 16HBE14o- model, PFC exposure led to significant apoptotic changes by 24 hours, with marked autophagic disruption. Nutrient deprivation, confirmed by starvation experiments, was a key driver of cytotoxicity due to media/PFC phase separation. Conversely, hSABCi cells in the ALI model remained viable, with no apoptosis or autophagic disruption over the exposure periods (P > 0.05 vs. control). Similarly, primary nasal AECs showed consistent viability and stability in autophagic and apoptotic markers, indicating a more accurate representation of in vivo conditions. TEER measurements and tight junction protein levels in the ALI model suggested PFC did not compromise epithelial integrity (P > 0.05 vs. control). PBS exposure, included as a liquid control, underscored baseline sensitivity in the primary nAEC model, evidenced by SQSTM1 upregulation and pronounced barrier dysfunction over 24-72 hours (P < 0.05-0.001). These findings underscore the unique biocompatibility of PFC in maintaining cellular integrity, in contrast to the disruptive effects observed with PBS. Conclusion: This is the first study to describe PFC exposure in an organotypic airway model. Results indicate that the ALI model more accurately preserves airway epithelial integrity during PFC exposure than submerged models, which are limited by nutrient depletion effects. The findings support the use of ALI cultures to replicate the human airway architecture for evaluating PFC's biological effects and offer a platform for preclinical applications in respiratory medicine. This organotypic approach may inform future therapeutic and hypoxia-related interventions and contributes significantly to the field by providing a viable model for understanding PFC interactions with airway epithelial cells. We are now trialling PFC emulsions that also contain azithromycin and steroid therapies for extended therapeutic applications.

Perfluorocarbon Gas Transport: an Overview of Medical History With Yet Unrealized Potentials

Perfluorocarbon-based oxygen carriers: from physics to physiology

Why Perfluorocarbon nanoparticles encounter bottlenecks in clinical translation despite promising oxygen carriers?

Perfluorocarbons: A perspective of theranostic applications and challenges

Recent Advances in Perfluorocarbon-Based Delivery Systems for Cancer Theranostics.

Oxygen therapeutics: perfluorocarbons and blood substitute safety

Blood Substitutes with Gas Transfer Function

Pathochemical toxicity of perfluorocarbon-5070, a liquid test performance fluid previously used in dialyzer manufacturing, confirmed in animal experiment

Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy

Artificial O2 carriers: status in 2005

Therapeutic Effect of Intravenous Infusion of Perfluorocarbon Emulsion on LPS-Induced Acute Lung Injury in Rats

Cross‐linked Triblock Peptide Capsules as Potential Oxygen Carriers

Perfluorocarbon Nanoparticles Incorporating GB: Artificial O2 Carrier with Antioxidant Activity and Antithrombotic Effect

Perfluorocarbons-Based 19F Magnetic Resonance Imaging in Biomedicine

Two-stage Oxygen Delivery for Enhanced Radiotherapy by Perfluorocarbon Nanoparticles

Organotypic tissue architecture is a requisite for predictive outcomes of perfluorocarbon exposure in airway models

Hollow fiber membrane modification with functional zwitterionic macromolecules for improved thromboresistance in artificial lungs.

Organofluorine compounds in artificial blood circulation systems

The therapeutic potential of hemoglobin-based oxygen carriers (HBOC) in the treatment of idiopathic pulmonary fibrosis

Hypothermic Peritoneal Perfusion of Cold Oxygenated Perfluorocarbon May Improve the Efficacy of Extracorporeal Oxygenation: A Mathematical Model-Based Analysis

Transcatheter Pulmonary Flow Restrictors: Current Trends and Future Perspectives